Sanofi

Sanofi, the French pharmaceutical giant, filed an initial Form 3 disclosing a significant ownership stake in Latigo Biotherapeutics, Inc. (ticker: LTGO), a pre-IPO biotech, effective August 6, 2026. Through wholly-owned subsidiaries, Sanofi holds Series B Preferred Stock convertible into 494,800 common shares and a Convertible Promissory Note convertible into 177,978 shares at the IPO price. Both instruments auto-convert upon closing of Latigo's IPO; the note otherwise matures June 17, 2027. The strategic investment signals Sanofi's early-stage interest in Latigo's pipeline.

Sanofi (Last) (First) (Middle) 46 AVENUE DE LA GRANDE ARMEE (Street) PARIS 75017 (City) (State) (Zip) FRANCE (Country) 2. Date of Event Requiring Statement (Month/Day/Year) 08/04/2026 3. Issuer Name and Ticker or Trading Symbol Attovia Therapeutics, Inc. [ ATTO ] 3a. Foreign Trading Symbol 5. If Amendment, Date of Original Filed (Month/Day/Year) 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Series C Preferred Stock (1) (1) Common Stock 782,855 (1) I (2) See footnote (2) Explanation of Responses: 1. The Series C preferred stock ("Preferred Stock") is convertible at the holder's option at any time into shares of the Issuer's common stock equal to dividing $1.375 by the conversion price applicable at the conversion time (which conversion price was $1.375 at the time of issuance of the Preferred Stock, as adjusted for certain anti-dilution and other adjustments described in the Issuer's Restated Certificate of Incorporation (the "Certificate")). The Preferred Stock ceases to be convertible upon certain events described in the Certificate, including certain redemptions and other events such as liquidations, dissolutions, or winding up of the Issuer. The Preferred Stock also converts in full automatically upon a Qualified Public Offering or at the Mandatory Conversion Time, each as defined in the Certificate. 2. Sanofi is the beneficial owner of the Preferred Stock through various wholly-owned subsidiaries. /s/ Alexandra Roger, as attorney-in-fact for Sanofi 08/04/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26) filed an initial statement of beneficial ownership (Form 3) as a Director of SNY, with an event date of 1473. The filer directly owns 782,855 shares of common stock. This is a routine insider-ownership disclosure with no indication of open-market purchases or activist intent.